Burden of systemic glucocorticoid-related complications in severe asthma

Abstract Objectives: Although systemic glucocorticoids (SGCs) are efficacious, their chronic use is associated with a range of complications. Yet limited data are available about the risks following chronic use in patients with severe asthma, who are at risk of long-term SGC-related complications. This study was carried out to investigate the risks of developing SGC-related complications, and to quantify the associated healthcare resource utilization and costs for patients with severe asthma in the United States. Methods: This was a longitudinal, open-cohort, observational study. Medicaid claims data (1997–2013) for patients ≥12 years old with ≥2 asthma diagnoses were used. A total of 26,987 SGC non-users were identified for inclusion in the study, alongside 3628 SGC users with ≥6 months’ continuous SGC use. Results: Multivariate generalized estimating equation models were used to estimate the adjusted risk of developing SGC-related complications, and to quantify the associated healthcare resource utilization and costs. This analysis compared SGC users with SGC non-users, and found that SGC users had an increased likelihood of developing complications. A significant dose–response relationship was demonstrated between chronic SGC use and risk of developing any complications (odds ratios for low, medium, and high SGC exposure were 2.03 [p = .0511], 2.85 [p < .0001], and 3.64 [p < .0001], respectively, vs. SGC non-users). The increased likelihood of SGC-related complications translated into estimated annual healthcare costs for SGC users of $2712 to $8560 above those of SGC non-users. A key limitation of this study is the disparity in age between the SGC users and the SGC non-users; however, age was included as a confounding factor in the analysis. Conclusions: These findings confirm the risk associated with chronic use of SGCs, irrespective of dose level, and highlight the need for new SGC-sparing treatment strategies for patients with severe asthma.

[1]  Anand A. Dalal,et al.  Dose-Response Relationship Between Long-Term Systemic Corticosteroid Use and Related Complications in Patients with Severe Asthma , 2016, Journal of managed care & specialty pharmacy.

[2]  Anand A. Dalal,et al.  Acute and chronic systemic corticosteroid-related complications in patients with severe asthma. , 2015, The Journal of allergy and clinical immunology.

[3]  M. Broder,et al.  Risk of corticosteroid-related adverse events in asthma patients with high oral corticosteroid use. , 2015, Allergy and asthma proceedings.

[4]  I. Pavord,et al.  Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. , 2014, The New England journal of medicine.

[5]  N. Thomson,et al.  The cost of treating severe refractory asthma in the UK: an economic analysis from the British Thoracic Society Difficult Asthma Registry , 2014, Thorax.

[6]  Jonathan D. Campbell,et al.  Characterizing the severe asthma population in the United States: claims-based analysis of three treatment cohorts in the year prior to treatment escalation , 2014, The Journal of asthma : official journal of the Association for the Care of Asthma.

[7]  M. Castro,et al.  Coexisting chronic conditions associated with mortality and morbidity in adult patients with asthma , 2014, The Journal of asthma : official journal of the Association for the Care of Asthma.

[8]  H. Kan,et al.  Cumulative burden of oral corticosteroid adverse effects and the economic implications of corticosteroid use in patients with systemic lupus erythematosus. , 2013, Clinical therapeutics.

[9]  C. Deal,et al.  Prevalence of oral glucocorticoid usage in the United States: A general population perspective , 2013, Arthritis care & research.

[10]  R. Silverman,et al.  Effect of asthma exacerbations on health care costs among asthmatic patients with moderate and severe persistent asthma. , 2012, The Journal of allergy and clinical immunology.

[11]  I. Petersen,et al.  Prevalence of long-term oral glucocorticoid prescriptions in the UK over the past 20 years. , 2011, Rheumatology.

[12]  L. Crofford,et al.  Incidence and US costs of corticosteroid-associated adverse events: a systematic literature review. , 2011, Clinical therapeutics.

[13]  S. Pakhalé,et al.  Optimal Management of Severe/Refractory Asthma , 2011, Clinical medicine insights. Circulatory, respiratory and pulmonary medicine.

[14]  C. Brightling,et al.  Refractory asthma in the UK: cross-sectional findings from a UK multicentre registry , 2010, Thorax.

[15]  J. Celedón,et al.  Asthma and ethnic minorities: socioeconomic status and beyond , 2009, Current opinion in allergy and clinical immunology.

[16]  M. Hernán,et al.  Prednisone, Lupus Activity, and Permanent Organ Damage , 2009, The Journal of Rheumatology.

[17]  S. Verstappen,et al.  Adverse events of low- to medium-dose oral glucocorticoids in inflammatory diseases: a meta-analysis , 2008, Annals of the rheumatic diseases.

[18]  Jesse B. Hall,et al.  Acute asthma in adults: a review. , 2004, Chest.

[19]  D. Postma,et al.  The ENFUMOSA cross-sectional European multicentre study of the clinical phenotype of chronic severe asthma , 2003, European Respiratory Journal.

[20]  B. Gudbjornsson,et al.  Prevalence of long term steroid treatment and the frequency of decision making to prevent steroid induced osteoporosis in daily clinical practice , 2002, Annals of the rheumatic diseases.

[21]  L. Magder,et al.  Damage in systemic lupus erythematosus and its association with corticosteroids. , 2000, Arthritis and rheumatism.

[22]  L Abenhaim,et al.  Use of oral corticosteroids in the United Kingdom. , 2000, QJM : monthly journal of the Association of Physicians.

[23]  G. Imbens.  The Role of the Propensity Score in Estimating Dose-Response Functions , 1999 .

[24]  Romain A. Pauwels.  GLOBAL STRATEGY FOR ASTHMA MANAGEMENT AND PREVENTION , 1996 .

[25]  M. Lara,et al.  Guidelines For The Diagnosis And Management Of Asthma , 1992, The Journal of the American Board of Family Medicine.

[26]  J. Baskerville,et al.  Bioequivalent doses of budesonide and prednisone in moderate and severe asthma. , 1989, The Journal of allergy and clinical immunology.

[27]  Rosalind Wright,et al.  Population disparities in asthma. , 2005, Annual review of public health.

[28]  C. Mackenzie,et al.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. , 1987, Journal of chronic diseases.

[29]  Brian H. Rowe,et al.  Umbrella Review : Corticosteroid Therapy for Adults ith Acute Asthma , 2022 .